This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tenet Healthcare (THC) Hits 52 Week High: Will the Rally Stay?
by Zacks Equity Research
Tenet Healthcare's (THC) shares display an upsurge as investors get optimistic about its latest strategic initiatives and cost-curbing measures.
Molina Healthcare (MOH) Up 86% in a Year: More Room to Run?
by Zacks Equity Research
Molina Healthcare (MOH) is well-poised to gain from a robust Medicare and Medicaid business, and numerous buyouts for boosting its service offerings.
Tenet (THC) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Tenet (THC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Apollo Medical Holdings, Inc. (AMEH) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Apollo Medical Holdings, Inc. (AMEH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Tenet Healthcare (THC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Tenet Healthcare (THC) closed at $55.62, marking a +0.07% move from the previous day.
Why Should You Hold HCA Healthcare (HCA) in Your Portfolio?
by Zacks Equity Research
Riding high on a solid 2021 outlook and strategic measures, HCA Healthcare (HCA) has enough potential to reap benefits for investors.
Is Tenet Healthcare (THC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (THC) Outperforming Other Medical Stocks This Year?
Tenet Healthcare (THC) Unit Extends Services to NorthShore
by Zacks Equity Research
Tenet Healthcare's (THC) unit Conifer extends alliance with NorthShore till 2024 with an aim to offer enhanced revenue cycle services to NorthShore.
Encompass Health (EHC) Ties Up for Better Homehealth Care
by Zacks Equity Research
Encompass Health (EHC) forms partnership with Right at Home for value-based care models, which in turn, are expected to improve health outcomes.
Universal Health (UHS) Q4 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
Universal Health's (UHS) fourth-quarter results reflect improved revenues across the company's segments, partly offset by elevated costs.
Tenet (THC) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Tenet (THC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Tenet Healthcare (THC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (THC) Outperforming Other Medical Stocks This Year?
Encompass Health (EHC) Unveils Plans to Expand in Maryland
by Zacks Equity Research
Encompass Health's (EHC) plans to construct a hospital is indicative of the company's efforts to offer improved healthcare services in southern Maryland.
Universal Health (UHS) to Report Q4 Results: What to Expect?
by Zacks Equity Research
Universal Health's (UHS) fourth-quarter results are likely to reflect gain from better revenues.
MEDNAX's (MD) Q4 Earnings Fall Shy of Estimates, Tumble Y/Y
by Zacks Equity Research
MEDNAX's (MD) fourth-quarter results reflect muted revenues caused by the COVID-19 pandemic.
Community Health's (CYH) Q4 Earnings Surpass, Improve Y/Y
by Zacks Equity Research
Community Health's (CYH) fourth-quarter earnings gain from lower costs. However, the same is offset to some extent by soft admissions.
Is Tenet Healthcare (THC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
4 Hospital Stocks to Gain From Growth in Patient Admissions
by Sapna Bagaria
Players in the hospital industry are likely to gain from increasing patient admissions, government grants and cost-control measures.
Tenet Healthcare (THC) Q4 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Tenet Healthcare's (THC) Q4 earnings improve on the back of better revenues.
What's in the Offing for Centene (CNC) This Earnings Season?
by Zacks Equity Research
Centene's (CNC) Q4 results are likely to reflect escalating costs and other COVID-related factors.
Tenet Healthcare (THC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Tenet (THC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cigna (CI) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Cigna's (CI) fourth-quarter results are likely to reflect strong performance across the business portfolio and lower SG&A costs, partly offset by continued COVID-19 related expenses.
Is Tenet Healthcare (THC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Top Ranked Momentum Stocks to Buy for February 1st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 1st
Humana (HUM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) fourth-quarter 2020 earnings might have endured escalating COVID-related expenses, partly offset by better revenues.